Genistein and hematological malignancies

Cancer Letters

Volumn 296, Issue 1, 2010, Pages 1-8

  Li, Wang ^a   Frame, Lynn T ^b   Hirsch, Samantha ^a   Cobos, Everardo ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Genistein; Hematological malignancy; Leukemia; Lymphoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; CD19 ANTIBODY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUDARABINE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; MITOGEN ACTIVATED PROTEIN KINASE; PREDNISONE; PTIG 2535; TAMOXIFEN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE ARREST; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOREGULATION; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MYALGIA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SINUS TACHYCARDIA; TOXICITY TESTING; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

GLYCINE MAX;

EID: 77954763057     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.002     Document Type: Review

References (68)

1. Adlercreutz H., Markkanen H., Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993, 342:1209-1210.
2. Mills P.K., Beeson W.L., Phillips R.L., Fraser G.E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989, 64:598-604.
3. Lampe J.W., Nishino Y., Ray R.M., Wu C., Li W., Lin M.G., Gao D.L., Hu Y., Shannon J., Stalsberg H., Porter P.L., Frankenfeld C.L., Wahala K., Thomas D.B. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2579-2586.
4. Kurahashi N., Iwasaki M., Sasazuki S., Otani T., Inoue M., Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol. Biomarkers Prev. 2007, 16:538-545.
5. Kanatani Y., Kasukabe T., Hozumi M., Motoyoshi K., Nagata N., Honma Y. Genistein exhibits preferential cytotoxicity to a leukemogenic variant but induces differentiation of a non-leukemogenic variant of the mouse monocytic leukemia Mm cell line. Leuk. Res. 1993, 17:847-853.
6. Mansour A., Chang V.T., Srinivas S., Harrison J., Raveche E. Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein. Cancer Immunol. Immunother. 2007, 56:501-514.
7. Okura A., Arakawa H., Oka H., Yoshinari T., Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun. 1988, 157:183-189.
8. Bandele O.J., Osheroff N. Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry 2007, 46:6097-6108.
9. Lopez-Lazaro M., Willmore E., Austin C.A. Cells lacking DNA topoisomerase II beta are resistant to genistein. J. Nat. Prod. 2007, 70:763-767.
10. Makishima M., Honma Y., Hozumi M., Sampi K., Hattori M., Umezawa K., Motoyoshi K. Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells. Leuk. Res. 1991, 15:701-708.
11. Jing Y., Waxman S. Structural requirements for differentiation-induction and growth-inhibition of mouse erythroleukemia cells by isoflavones. Anticancer Res. 1995, 15:1147-1152.
12. Constantinou A., Kiguchi K., Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res. 1990, 50:2618-2624.
13. Chen Y.H., Tang Y.M., Shen H.Q., Song H., Yang S.L., Shi S.W., Qian B.Q., Xu W.Q., Ning B.T. Targeted killing of the Nalm-6 cells with 2E8-genistein immunotoxin and its mechanism. Zhonghua Er Ke Za Zhi 2009, 47:57-61.
14. He H., Chen L., Zhai M., Chen J.Z. Genistein down-regulates the constitutive activation of nuclear factor-kappaB in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Phytother. Res. 2009, 23:868-873.
15. Sanchez Y., Amran D., Fernandez C. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MPK, AMPK). Int. J. Cancer 2008, 123:1205-1214.
16. Park S.S., Kim Y.N., Jeon Y.K., Kim Y.A., Kim J.E., Kim H., Kim C.W. Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma. Cancer Chemother. Pharmacol. 2005, 56:271-278.
17. Baxa D.M., Luo X., Yoshimura F.K. Genistein induces apoptosis in T lymphoma cells via mitochondrial damage. Nutr. Cancer 2005, 51:93-101.
18. Ng A.P., Nin D.S., Fong J.H., Venkataraman D., Chen C.S., Khan M. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. Mol. Cancer Ther. 2007, 6:2240-2248.
19. Shen J., Zhang W.J., Tai Y.C., Wong C.H., Xie Z., Chen C.S. Synergistic antileukemic effect of phytoestrogens and chemotherapeutic drugs on leukemic cell lines in vitro. Zhongguo Shi Yan Xue Za Zhi 2008, 16:276-281.
20. Bergamaschi G., Rosti V., Danova M., Ponchio L., Lucotti C., Cazzola M. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia 1993, 7:2012-2018.
21. Yamasaki M., Fujita S., Ishiyama E., Mukai A., Madhyastha H., Sakakibara Y., Suiko M., Hatakeyama K., Nemoto T., Morishita K., Kataoka H., Tsubouchi H., Nishiyama K. Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci. 2007, 98:1740-1746.
22. Finlay G.J., Holdaway K.M., Baguley B.C. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. Oncol. Res. 1994, 6:33-37.
23. Spinozzi F., Pagliacci M.C., Migliorati G., Moraca R., Grignani F., Riccardi C., Nicoletti I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 1994, 18:431-439.
24. Jamadar-Shroff V., Papich M.G., Suter S.E. Soy-derived isoflavones inhibit the growth of canine lymphoid cell lines. Clin. Cancer Res. 2009, 15:1269-1276.
25. Myers D.E., Jun X., Waddick K.G., Forsyth C., Chelstrom L.M., Gunther R.L., Tumer N.E., Bolen J., Uckun F.M. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Proc. Natl. Acad. Sci. USA 1995, 92:9575-9579.
26. Polkowski K., Skierski J.S., Mazurek A.P. Anticancer activity of genistein-piperazine complex. In vitro study with HL-60 cells. Acta Pol. Pharm. 2000, 57:223-232.
27. McCall J.L., Burich R.A., Mack P.C. GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk. Res. 2009.
28. Traganos F., Ardelt B., Halko N., Bruno S., Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res. 1992, 52:6200-6208.
29. Jeong M.H., Jin Y.H., Kang E.Y., Jo W.S., Park H.T., Lee J.D., Yoo Y.J., Jeong S.J. The modulation of radiation-induced cell death by genistein in K562 cells: activation of thymidine kinase 1. Cell Res. 2004, 14:295-302.
30. Shen J., Tai Y.C., Zhou J., Stephen Wong C.H., Cheang P.T., Fred Wong W.S., Xie Z., Khan M., Han J.H., Chen C.S. Synergistic antilekemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp. Hematol. 2007, 35:75-83.
31. Mohammad R.M., Al-Katib A., Aboukameel A., Doerge D.R., Sarkar F., Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol. Cancer Ther. 2003, 2:1361-1368.
32. Sanchez Y., Amran D., de Blas E., Aller P. Regulation of genistein-induced differentiation in human acute myeloid leukaemia cells (HL60, NB4) Protein kinase modulation and reactive oxygen species generation. Biochem. Pharmacol. 2009, 77:384-396.
33. Baxa D.M., Yoshimura F.K. Genistein reduces NF-kappa B in T lymphoma cells via a caspase-mediated cleavage of I kappa B alpha. Biochem. Pharmacol. 2003, 66:1009-1018.
34. Carey G.B., Liberti J.P. Stimulation of receptor-associated kinase, tyrosine kinase, and MAP kinase is required for prolactin-mediated macromolecular biosynthesis and mitogenesis in Nb2 lymphoma. Arch. Biochem. Biophys. 1995, 316:179-189.
35. Park J., Chung S.W., Kim S.H., Kim T.S. Up-regulation of interleukin-4 production via NF-AT/AP-1 activation in T cells by biochanin A, a phytoestrogen and its metabolites. Toxicol. Appl. Pharmacol. 2006, 212:188-199.
36. Shimo K., Gyotoku Y., Arimitsu Y., Kakiuchi T., Mizuguchi J. Participation of tyrosine kinase in capping, internalization, and antigen presentation through membrane immunoglobulin in BAL17 B lymphoma cells. FEBS Lett. 1993, 323:171-174.
37. Hunakova L., Sedlak J., Klobusicka M., Duraj J., Chorvath B. Tyrosine kinase inhibitor-induced differentiation of K-562 cells: alterations of cell cycle and cell surface phenotype. Cancer Lett. 1994, 81:81-87.
38. Alexandrakis M.G., Kyriakou D.S., Kempuraj D., Huang M., Boucher W., Seretakis D., Theoharides T.C. The isoflavone genistein inhibits proliferation and increases histamine content in human leukemic mast cells. Allergy Asthma Proc. 2003, 24:373-377.
39. Yun J., Lee C.K., Chang I.M., Takatsu K., Hirano T., Min K.R., Lee M.K., Kim Y. Differential inhibitory effects of sophoricoside analogs on bioactivity of several cytokines. Life Sci. 2000, 67:2855-2863.
40. Deora A.B., Miranda M.B., Rao S.G. Down-modulation of P210bcr/abl induces apoptosis/differentiation in K562 leukemic blast cells. Tumori 1997, 83:756-761.
41. Zhou Y., Lee A.S. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J. Natl. Cancer Inst. 1998, 90:381-388.
42. Zhang D., Tai Y.C., Wong C.H., Tai L.K., Koay E.S., Chen C.S. Molecular response of leukemia HL-60 cells to genistein treatment, a proteomics study. Leuk. Res. 2007, 31:75-82.
43. Martinez-Lorenzo M.J., Anel A., Monleon I., Sierra J.J., Pineiro A., Naval J., Alava M.A. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int. J. Biochem. Cell Biol. 2000, 32:435-445.
44. Kim M.H., Albertsson P., Xue Y., Nannmark U., Kitson R.P., Goldfarb R.H. Expression of neutrophil collagenase (MMP-8) in Jurkat T leukemia cells and its role in invasion. Anticancer Res. 2001, 21:45-50.
45. Ito T., Warnken S.P., May W.S. Protein synthesis inhibition by flavonoids: roles of eukaryotic initiation factor 2alpha kinases. Biochem. Biophys. Res. Commun. 1999, 265:589-594.
46. Thors L., Alajakku K., Fowler C.J. The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br. J. Pharmacol. 2007, 150:951-960.
47. Thors L., Eriksson J., Fowler C.J. Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake. Br. J. Pharmacol. 2007, 152:744-750.
48. Boadi W.Y., Iyere P.A., Adunyah S.E. In vitro exposure to quercetin and genistein alters lipid peroxides and prevents the loss of glutathione in human progenitor mononuclear (U937) cells. J. Appl. Toxicol. 2005, 25:82-88.
49. Smal C., Cardoen S., Bertrand L., Delacauw A., Ferrant A., Van den Berghe G., Van den Neste E., Bontemps F. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem. Pharmacol. 2004, 68:95-103.
50. Huang C.C., Chang C.B., Liu J.Y., Basavappa S., Lim P.H. Effects of calcium, calmodulin, protein kinase C and protein tyrosine kinases on volume-activated taurine efflux in human erythroleukemia cells. J. Cell Physiol. 2001, 189:316-322.
51. Lee R., Kim Y.J., Lee Y.J., Chung H.W. The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Toxicology 2004, 195:87-95.
52. Carlo-Stella C., Dotti G., Mangoni L., Regazzi E., Garau D., Bonati A., Almici C., Sammarelli G., Savoldo B., Rizzo M.T., Rizzoli V. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996, 88:3091-3100.
53. Hirano T., Gotoh M., Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 1994, 55:1061-1069.
54. Siwinska A., Opolski A., Chrobak A., Wietrzyk J., Wojdat E., Kutner A., Szelejewski W., Radzikowski C. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res. 2001, 21:1925-1929.
55. Raynal N.J., Charbonneau M., Momparler L.F., Momparler R.L. Synergistic effect of 5-Aza-2′-deoxycytidine and genistein in combination against leukemia. Oncol. Res. 2008, 17:223-230.
56. Danel L., Menouni M., Cohen J.H., Magaud J.P., Lenoir G., Revillard J.P., Saez S. Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. Leuk. Res. 1985, 9:1373-1378.
57. Otsuki T., Yamada O., Kurebayashi J., Moriya T., Sakaguchi H., Kunisue H., Yata K., Uno M., Yawata Y., Ueki A. Estrogen receptors in human myeloma cells. Cancer Res. 2000, 60:1434-1441.
58. Gauduchon J., Gouilleux F., Maillard S., Marsaud V., Renoir M.J., Sola B. The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. Ann. NY Acad. Sci. 2003, 1010:321-325.
59. Treon S.P., Teoh G., Urashima M., Ogata A., Chauhan D., Webb I.J., Anderson K.C. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 1998, 92:1749-1757.
60. Decaudin D., Etienne M.C., De Cremoux P., Maciorowski Z., Vantelon J.M., Voog E., Urien S., Tran-Perennou C., Renee N., Vielh P., Nemati F., Pouillart P. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma. J. Natl. Cancer Inst. 2004, 96:636-637.
61. Urbinati G., Audisio D., Marsaud V., Plassat V., Arpicco S., Sola B., Fattal E., Renoir J.M. Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model. Pharm. Res. 2010, 27:327-339.
62. Faqi A.S., Johnson W.D., Morrissey R.L., McCormick D.L. Reproductive toxicity assessment of chronic dietary exposure to soy isoflavones in male rats. Reprod. Toxicol. 2004, 18:605-611.
63. Uckun F.M., Evans W.E., Forsyth C.J., Waddick K.G., Ahlgren L.T., Chelstrom L.M., Burkhardt A., Bolen J., Myers D.E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995, 267:886-891.
64. Myers D.E., Sicheneder A., Clementson D., Dvorak N., Venkatachalam T., Sev A.R., Chandan-Langlie M., Uckun F.M. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma. Leuk. Lymphoma 1998, 29:329-338.
65. Ek O., Yanishevski Y., Zeren T., Waurzyniak B., Gunther R., Chelstrom L., Chandan-Langlie M., Schneider E., Myers D.E., Evans W., Uckun F.M. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. Leuk. Lymphoma 1998, 30:389-394.
66. Messinger Y., Yanishevski Y., Ek O., Zeren T., Waurzyniak B., Gunther R., Chelstrom L., Chandan-Langlie M., Schneider E., Myers D.E., Evans W., Uckun F.M. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin. Cancer Res. 1998, 4:165-170.
67. Chen C.L., Levine A., Rao A., O'Neill K., Messinger Y., Myers D.E., Goldman F., Hurvitz C., Casper J.T., Uckun F.M. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J. Clin. Pharmacol. 1999, 39:1248-1255.
68. Uckun F.M., Messinger Y., Chen C.L., O'Neill K., Myers D.E., Goldman F., Hurvitz C., Casper J.T., Levine A. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin. Cancer Res. 1999, 12:3906-3913.